Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Moussa, Charbel; Hebron, Michaeline; Huang, Xu; Ahn, Jaeil; Rissman, Robert A.; Aisen, Paul S.; Turner, R. Scott

doi:10.1186/s12974-016-0779-0

Cited by 539 publications

(380 citation statements)

References 52 publications

(50 reference statements)

Supporting

Mentioning

366

Contrasting

Order By: Relevance

“…This compound, together with its dimer trans ‐ε‐viniferin, may improve cognition by modulating GABA A R‐induced currents (Moussa et al . ). In the study performed by Moussa et al .…”

Section: Allosteric Modulators Of Gabaa Receptorsmentioning

confidence: 97%

The GABAergic system as a therapeutic target for Alzheimer's disease

Guzmán

Vinnakota

Govindpani

et al. 2018

Journal of Neurochemistry

116

View full text Add to dashboard Cite

Glutamatergic and cholinergic dysfunction are well-attested features of Alzheimer's disease (AD), progressing with other pathological indices of the disorder and exacerbating neuronal and network dysfunction. However, relatively little attention has been paid to the inhibitory component of the excitatory/inhibitory (E/I) network, particularly dysfunction in the gamma-aminobutyric acid (GABA) signaling system. There is growing evidence in support of GABAergic remodeling in the AD brain, potentially beginning in early stages of disease pathogenesis, and this could thus be a valid molecular target for drug development and pharmacological therapies. Several GABAergic drugs have been tested for efficacy in attenuating or reversing various features and symptoms of AD, and this could represent a novel path by which we might address the growing need for more effective and benign therapies.

show abstract

“…This compound, together with its dimer trans ‐ε‐viniferin, may improve cognition by modulating GABA A R‐induced currents (Moussa et al . ). In the study performed by Moussa et al .…”

Section: Allosteric Modulators Of Gabaa Receptorsmentioning

confidence: 97%

The GABAergic system as a therapeutic target for Alzheimer's disease

Guzmán

Vinnakota

Govindpani

et al. 2018

Journal of Neurochemistry

116

View full text Add to dashboard Cite

show abstract

“…Taken together these observations suggest that resveratrol may slow down a cognitive decline through a coordinated peripheral and central immune response. These encouraging results are a starting point to further validating the neuroprotective effects of resveratrol (Moussa et al, ).…”

Section: Polyphenol Neuroprotective Potentialmentioning

confidence: 75%

Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?

Squillaro

Schettino

Sampaolo

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

Aging is a primary risk factor for both neurodegenerative disorders (NDs) and tumors such as adult-onset brain tumors. Since NDs and tumors are severe, disabling, progressive and often incurable conditions, they represent a pressing problem in terms of human suffering and economic costs to the healthcare systems. The current challenge for physicians and researchers is to develop new therapeutic strategies in both areas to improve the patients' quality of life. In addition to genetics and environmental stressors, the increase in cellular oxidative stress as one of the potential common etiologies has been reported for both disorders. Recently, the scientific community has focused on the beneficial effects of dietary antioxidant classes, known as nutraceuticals, such as carotenoids, vitamins, and polyphenols. Among these compounds, polyphenols are considered to be one of the most bioactive agents in neurodegeneration and tumor prevention. Despite the beneficial activity of polyphenols, their poor bioavailability and inefficient delivery systems are the main factors limiting their use in medicine and functional food. The development of polymeric nanoparticle-based delivery systems able to encapsulate and preserve polyphenolic compounds may represent a promising tool to enhance their stability, solubility, and cell membrane permeation. In the present review we provide an overview of the main polyphenolic compounds used for ND and brain tumor prevention and treatment that explores their mechanisms of action, recent clinical findings and principal factors limiting their application in medicine.

show abstract

“…To probe numerous analytes, we utilize the Luminex xMAP technology [11, 15, 17, 24]. Kidney injury analytes were measured in serum with the Mouse Kidney Injury Magnetic Bead Panel 1 (Cat MKI1MAG-94K, EMD Millipore).…”

Section: Methodsmentioning

confidence: 99%

Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy

Javidnia

Hebron

Xin

et al. 2017

JAD

View full text Add to dashboard Cite

Hyperphosphorylation and aggregation of tau protein is a critical factor in many neurodegenerative diseases. These diseases are increasing in prevalence, and there are currently no cures. Previous work from our group and others has shown that tyrosine kinase inhibitors (TKIs) can stimulate autophagy, decrease pathological proteins, and improve symptoms in models of neurodegeneration. Here we examined the role of pazopanib in mouse models that express either human mutant P301L tau (TauP301L) or triple mutant amyloid precursor protein (3x-AβPP). The TauP301L mouse expresses P301L tau under the control of a prion promoter in both neurons and astrocytes, reminiscent of some human tauopathies. Pazopanib crosses the blood-brain barrier with no detectable peripheral off-side effects, and decreases p-tau in TauP301L mice. Pazopanib reaches a brain concentration sufficient for inhibition of several tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs). Further, pazopanib does not affect microglia but reduces astrocyte levels toward nontransgenic controls in TauP301L mice. Pazopanib does not alter amyloid beta levels or astrocytes in 3x-AβPP mice but modulates a number of inflammatory markers (IP-10, MIP-1α, MIP-1β, and RANTES). These data suggest that pazopanib may be involved in p-tau clearance and modulation of astrocytic activity in models of tauopathies.

show abstract

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Cited by 539 publications

References 52 publications

The GABAergic system as a therapeutic target for Alzheimer's disease

The GABAergic system as a therapeutic target for Alzheimer's disease

Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?

Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy

Contact Info

Product

Resources

About